STOCK TITAN

Janux Therapeutics Announces Updates to Board of Directors

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Positive)
Tags
management

Janux Therapeutics (Nasdaq: JANX) has announced significant updates to its Board of Directors. Eric Dobmeier and Natasha Hernday have been appointed to the board, bringing extensive operational and business development experience. Eric Dobmeier, former CEO of Chinook Therapeutics, has over 20 years of biotech industry experience. Natasha Hernday, previously Chief Business Officer at Seagen Inc., has a strong track record in strategic partnerships and acquisitions.

Additionally, Jay Lichter, Ph.D., has resigned from the board, and Ronald W. Barrett, Ph.D., a current board member, has been appointed as Chairperson. These changes aim to support Janux's corporate and pipeline strategy as it advances its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms in developing novel immunotherapies for cancer treatment.

Janux Therapeutics (Nasdaq: JANX) ha annunciato aggiornamenti significativi al suo Consiglio di Amministrazione. Eric Dobmeier e Natasha Hernday sono stati nominati membri del consiglio, portando con sé una vasta esperienza operativa e nello sviluppo del business. Eric Dobmeier, ex CEO di Chinook Therapeutics, vanta oltre 20 anni di esperienza nell'industria biotech. Natasha Hernday, precedentemente Chief Business Officer di Seagen Inc., ha un forte curriculum nelle partnership strategiche e nelle acquisizioni.

Inoltre, Jay Lichter, Ph.D., si è dimesso dal consiglio, e Ronald W. Barrett, Ph.D., attuale membro del consiglio, è stato nominato presidente. Questi cambiamenti mirano a supportare la strategia aziendale e di pipeline di Janux mentre progredisce nelle sue piattaforme di Tumor Activated T Cell Engager (TRACTr) e Tumor Activated Immunomodulator (TRACIr) per lo sviluppo di nuove immunoterapie per il trattamento del cancro.

Janux Therapeutics (Nasdaq: JANX) ha anunciado actualizaciones significativas en su Junta Directiva. Eric Dobmeier y Natasha Hernday han sido nombrados para la junta, aportando una amplia experiencia en operaciones y desarrollo empresarial. Eric Dobmeier, ex CEO de Chinook Therapeutics, cuenta con más de 20 años de experiencia en la industria biotecnológica. Natasha Hernday, anteriormente Directora de Negocios en Seagen Inc., tiene un sólido historial en asociaciones estratégicas y adquisiciones.

Además, Jay Lichter, Ph.D., ha renunciado a la junta, y Ronald W. Barrett, Ph.D., un miembro actual de la junta, ha sido nombrado presidente. Estos cambios tienen como objetivo apoyar la estrategia corporativa y de pipeline de Janux mientras avanza en sus plataformas de Tumor Activated T Cell Engager (TRACTr) y Tumor Activated Immunomodulator (TRACIr) para el desarrollo de nuevas inmunoterapias para el tratamiento del cáncer.

Janux Therapeutics (Nasdaq: JANX)는 이사회의 주요 업데이트를 발표했습니다. Eric DobmeierNatasha Hernday가 이사회에 임명되어 광범위한 운영 및 사업 개발 경험을 가져왔습니다. Eric Dobmeier는 Chinook Therapeutics의 전 CEO로, 생명공학 산업에서 20년 이상의 경험을 보유하고 있습니다. Natasha Hernday는 이전에 Seagen Inc.의 최고 사업 책임자로서 전략적 파트너십 및 인수에 대한 강력한 실적을 가지고 있습니다.

또한 Jay Lichter 박사는 이사직을 사임하였고, Ronald W. Barrett 박사, 현재 이사회의 일원이 의장으로 임명되었습니다. 이러한 변화는 Janux의 기업 및 파이프라인 전략을 지원하는 것을 목표로 하며, 새로운 면역 치료제를 개발하기 위해 Tumor Activated T Cell Engager (TRACTr)Tumor Activated Immunomodulator (TRACIr) 플랫폼을 발전시키고 있습니다.

Janux Therapeutics (Nasdaq: JANX) a annoncé des mises à jour significatives de son Conseil d'Administration. Eric Dobmeier et Natasha Hernday ont été nommés au conseil, apportant une vaste expérience opérationnelle et en développement commercial. Eric Dobmeier, ancien PDG de Chinook Therapeutics, possède plus de 20 ans d'expérience dans l'industrie biotechnologique. Natasha Hernday, précédemment Directrice des Affaires chez Seagen Inc., a un solide bilan en matière de partenariats stratégiques et d'acquisitions.

De plus, Jay Lichter, Ph.D., a démissionné du conseil, et Ronald W. Barrett, Ph.D., un membre actuel du conseil, a été nommé président. Ces changements visent à soutenir la stratégie corporative et de pipeline de Janux alors qu'elle fait progresser ses plateformes de Tumor Activated T Cell Engager (TRACTr) et Tumor Activated Immunomodulator (TRACIr) pour développer de nouvelles immunothérapies dans le traitement du cancer.

Janux Therapeutics (Nasdaq: JANX) hat bedeutende Aktualisierungen seines Vorstands bekannt gegeben. Eric Dobmeier und Natasha Hernday wurden in den Vorstand berufen und bringen umfangreiche Erfahrungen in den Bereichen Betrieb und Geschäftsentwicklung mit. Eric Dobmeier, ehemaliger CEO von Chinook Therapeutics, hat über 20 Jahre Erfahrung in der Biotechnologiebranche. Natasha Hernday, ehemals Chief Business Officer bei Seagen Inc., hat eine starke Erfolgsbilanz in strategischen Partnerschaften und Akquisitionen.

Darüber hinaus hat Jay Lichter, Ph.D., sein Amt im Vorstand niedergelegt, und Ronald W. Barrett, Ph.D., ein aktuelles Mitglied des Vorstands, wurde zum Vorsitzenden ernannt. Diese Änderungen zielen darauf ab, die Unternehmens- und Pipeline-Strategie von Janux zu unterstützen, während das Unternehmen seine Tumor Activated T Cell Engager (TRACTr) und Tumor Activated Immunomodulator (TRACIr) Plattformen zur Entwicklung neuartiger Immuntherapien für die Krebsbehandlung vorantreibt.

Positive
  • Appointment of Eric Dobmeier and Natasha Hernday brings valuable industry experience to the board
  • Eric Dobmeier has raised over $2 billion in equity capital during his career
  • Natasha Hernday has a successful track record in high-value transactions, including Seagen's $43 billion acquisition by Pfizer
  • Janux's pipeline includes two clinical candidates: JANX007 and JANX008, currently in Phase 1 trials
Negative
  • Resignation of Jay Lichter, a key figure from founding seed investor Avalon Ventures, from the Board of Directors
  • The appointment of Eric Dobmeier and Natasha Hernday to the Board brings extensive operational and business development experience to support corporate and pipeline strategy
  • Janux also announced the resignation of Jay Lichter, Ph.D., from the Board, and the appointment of current Board member Ronald W. Barrett, Ph.D., as Chairperson

SAN DIEGO--(BUSINESS WIRE)-- Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the appointment of Eric Dobmeier and Natasha Hernday to its Board of Directors.

“Eric and Natasha’s vast experience and proven leadership in the biopharmaceutical industry are tremendous assets for Janux at this pivotal stage of our growth,” said David Campbell, Ph.D., President and CEO of Janux Therapeutics. “Eric’s extensive experience in biopharmaceutical operations and strategic growth will be invaluable as Janux continues to advance its pipeline. Natasha’s background in corporate strategy and identifying, executing and managing high-value partnerships will be essential as Janux looks to expand its opportunities to further its mission in developing next-generation cancer therapies.”

Dr. Campbell continued, “Their contributions will not only enhance our strategic direction but ultimately benefit patients through the potential development of next-generation cancer therapies. We are excited to welcome them to our Board and look forward to their contributions.”

Eric Dobmeier, J.D. has more than 20 years of experience in the biotechnology industry as both an executive and board member. Most recently, he was the President and CEO of Chinook Therapeutics, where he led the company through multiple strategic growth initiatives ultimately leading to its acquisition by Novartis in 2023 for $3.5 billion. Prior to Chinook, Mr. Dobmeier spent 16 years in a series of positions of increasing responsibility at Seattle Genetics, including Chief Operating Officer, during the company’s growth from 60 to 1,200 employees, from a market cap of $150 million to over $8 billion and through its transition to a commercial company with FDA approval and launch of Adcetris, a novel lymphoma drug. During his career, Mr. Dobmeier has been directly involved in raising more than $2 billion in equity capital and led negotiation of many corporate alliances with leading biotechnology and pharmaceutical companies. He is currently a venture partner at Samsara Biocapital and serves on the boards of directors of Structure Therapeutics and Abdera Therapeutics.

Natasha Hernday previously served as Chief Business Officer and a member of the Executive Committee at Seagen Inc. (formerly Seattle Genetics) and was pivotal in driving business development, including alliance management, strategic partnerships, mergers, and acquisitions. Ms. Hernday led the acquisition of Cascadian Therapeutics in 2018 for approximately $614 million and a global strategic oncology collaboration with Merck in 2020 for over $1.5 billion in upfront cash and equity. Cascadian’s lead asset has since been approved and is achieving over $400 million in yearly revenue. Ms. Hernday’s strategic insight and successful track record in transactions culminated in Seagen's acquisition by Pfizer in 2023 for $43 billion. Prior to her role at Seagen, Ms. Hernday spent 16 years at Amgen, where she began her career in discovery research, then held various leadership positions in corporate development and corporate strategy, including as Director, Mergers & Acquisitions and as Director, Out-Partnering, playing a key role in numerous high-value transactions. Additionally, Ms. Hernday served on the Board of Alpine Immune Sciences, which was acquired by Vertex Pharmaceuticals in 2024 for $4.9 billion.

In addition, Janux announced the resignation of Jay Lichter, Ph.D., from the Board of Directors. Dr. Lichter, a key figure as the head of Janux’s founding seed investor Avalon Ventures, has been instrumental in the company’s growth and success. Current Board member Ronald W. Barrett, Ph.D., will replace Jay Lichter as Chairperson of the Board.

“We deeply appreciate Jay’s leadership and dedication over the years,” said Dr. Campbell. “His vision and commitment have been integral to our achievements, and for that, we thank him deeply. Ron’s extensive experience and leadership in the biopharmaceutical industry will be vital as Janux continues to advance its innovative pipeline, and I look forward to his continued stewardship and contributions.”

Janux’s TRACTr and TRACIr Pipeline

Janux’s first clinical candidate, JANX007, is a TRACTr that targets PSMA and is being investigated in a Phase 1 clinical trial in adult subjects with metastatic castration-resistant prostate cancer (mCRPC). Janux’s second clinical candidate, JANX008, is a TRACTr that targets EGFR and is being studied in a Phase 1 clinical trial for the treatment of multiple solid cancers including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. We are also generating a number of additional TRACTr and TRACIr programs for potential future development, some of which are at development candidate stage or later. We are currently assessing priorities in our preclinical pipeline.

About Janux Therapeutics

Janux is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Janux’s proprietary technology enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The goal of both platforms is to provide cancer patients with safe and effective therapeutics that direct and guide their immune system to eradicate tumors while minimizing safety concerns. Janux is currently developing a broad pipeline of TRACTr and TRACIr therapeutics directed at several targets to treat solid tumors. Janux has two TRACTr therapeutic candidates in clinical trials, the first targeting PSMA is in development for prostate cancer, and the second targeting EGFR is being developed for colorectal, lung, head and neck, and renal cancers. For more information, please visit www.januxrx.com and follow us on LinkedIn.

Forward-Looking Statements

This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, Janux’s ability to bring new treatments to cancer patients in need, expectations regarding the timing, scope and results of Janux’s development activities, including its ongoing and planned preclinical studies and clinical trials, the potential benefits of Janux’s product candidates and platform technologies and expectations regarding the use of Janux’s platform technologies to generate novel product candidates. Factors that may cause actual results to differ materially include the risk that compounds that appear promising in early research do not demonstrate safety and/or efficacy in later preclinical studies or clinical trials, the risk that Janux may not obtain approval to market its product candidates, uncertainties associated with performing clinical trials, regulatory filings and applications, risks associated with reliance on third parties to successfully conduct clinical trials, the risks associated with reliance on outside financing to meet capital requirements, and other risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. You are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,” “promise,” “potential,” “expects,” “plans,” “anticipates,” “intends,” “continues,” “designed,” “goal,” or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties Janux faces, please refer to Janux’s periodic and other filings with the Securities and Exchange Commission, which are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and Janux assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Investors:

Andy Meyer

Janux Therapeutics

ameyer@januxrx.com

(202) 215-2579

Media:

Jessica Yingling, Ph.D.

Little Dog Communications Inc.

jessica@litldog.com

(858) 344-8091

Source: Janux Therapeutics

FAQ

Who are the new board members appointed to Janux Therapeutics (JANX)?

Eric Dobmeier and Natasha Hernday have been appointed to the Board of Directors of Janux Therapeutics (JANX).

What experience do the new Janux Therapeutics (JANX) board members bring?

Eric Dobmeier brings over 20 years of biotech industry experience, including leadership roles at Chinook Therapeutics and Seattle Genetics. Natasha Hernday has extensive experience in business development, strategic partnerships, and high-value transactions from her roles at Seagen Inc. and Amgen.

Who has been appointed as the new Chairperson of Janux Therapeutics (JANX)?

Ronald W. Barrett, Ph.D., a current board member, has been appointed as the new Chairperson of Janux Therapeutics (JANX), replacing Jay Lichter, Ph.D., who has resigned from the board.

What are the main clinical candidates in Janux Therapeutics' (JANX) pipeline?

Janux Therapeutics' (JANX) main clinical candidates are JANX007, targeting PSMA for metastatic castration-resistant prostate cancer, and JANX008, targeting EGFR for multiple solid cancers. Both are currently in Phase 1 clinical trials.

Janux Therapeutics, Inc.

NASDAQ:JANX

JANX Rankings

JANX Latest News

JANX Stock Data

2.70B
47.10M
7.75%
94.58%
8.24%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SAN DIEGO